Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06098833
Other study ID # SANE-03
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date November 2023
Est. completion date June 2028

Study information

Verified date October 2023
Source McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact Pia Wintermark, MD
Phone +1-514-412-4452
Email pia.wintermark@mcgill.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Around the time of birth, some babies experience a condition called asphyxia, which means that their brain and other organs do not receive enough blood and/or oxygen to work properly. This life-threatening condition accounts for nearly 1 out of 4 deaths of all babies around the world, and often leads to severe brain damage, cerebral palsy, epilepsy, and trouble with learning and functioning in everyday life. At this time, no treatment is available to repair the brain damage caused by asphyxia. Excitingly, a drug called sildenafil (Viagra®) is already given safely to babies who suffer from increased blood pressure in their lungs' vessels. Recent studies using a laboratory model of asphyxia at birth suggest that sildenafil may also repair the brain damage caused by asphyxia. Similarly, recent small studies have shown that it is both feasible and safe to give sildenafil to human babies, who suffered from asphyxia at birth. These studies also highlight the first promising signs that sildenafil may improve how the brains of these babies work, which is consistent with the abovementioned laboratory studies. On the basis of these previous researches, the investigators predict that sildenafil can repair the damage to a baby's brain. The investigators will test whether sildenafil can be safely given to a large group of human babies who suffer from asphyxia at birth, and will confirm whether sildenafil improves or not how their brains and hearts/lungs work. This project will enable to determine whether sildenafil is a promising treatment for repairing brain damage in babies who suffer from asphyxia at birth. This project may also provide new solutions for these babies to improve their future life.


Description:

The investigators will enroll neonates with HIE treated with TH from NICUs in a multicentre, randomized, double-blind, placebo-controlled phase 2 clinical trial to evaluate the safety and efficacy of sildenafil to repair brain injury. Neonates with moderate-severe HIE on admission and with brain injury on a day-2 brain MRI (during TH) will be randomized to sildenafil or placebo (allocation 2:1) for 7 consecutive days. Aim 1: Evaluate the efficacy of sildenafil to improve brain injury (primary outcome). The investigators will determine whether sildenafil reduces brain injury on a day-30 MRI compared to the baseline day-2 MRI. Aim 2: Determine the safety of sildenafil (secondary outcome). The investigators will assess the safety of sildenafil by recording the incidence of adverse events. Aim 3: Evaluate the efficacy of sildenafil to improve cardiopulmonary hemodynamics (secondary outcome). The investigators will determine whether sildenafil improves pulmonary pressure and right/left ventricular function on day 4 of life (after TH completion) compared to baseline day-2 measurements


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date June 2028
Est. primary completion date October 2027
Accepts healthy volunteers No
Gender All
Age group 0 Minutes to 48 Hours
Eligibility Inclusion Criteria: - Male and female neonates meeting the criteria for induced hypothermia: - Gestational age =36weeks and birth weight =1800g; - Evidence of fetal distress, i.e., history of an acute perinatal event, cord pH =7.0 or base deficit - 16 mEq/L; - Evidence of neonatal distress, such as an Apgar score =5 at 10 minutes, postnatal blood gas pH obtained within the first hour of life = 7.0 or base deficit = - 16 mEq/L, or a continued need for ventilation initiated at birth and continued for at least 10 minutes; - Evidence of moderate to severe neonatal encephalopathy by an abnormal neurological exam and/or an amplitude-integrated electroencephalogram (aEEG). They will receive whole-body cooling to an esophageal temperature of 33.5°C, initiated within the first 6 hours of life, continued for 72 hours, and then they will be slowly rewarmed using standard protocol. - Evidence of brain injury on a brain magnetic resonance imaging (MRI) performed on day 2 of life. Exclusion Criteria: - Neonates with complex congenital heart disease - Neonates with cerebral malformations - Neonates with genetic syndrome - Neonates with intraventricular and/or intraparenchymal hemorrhage on MRI performed on day 2 of life - Moribund infants not expected to survive

Study Design


Intervention

Drug:
Sildenafil
Sildenafil per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
Ora-Blend
Ora-Blend per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)

Locations

Country Name City State
Canada Montreal Children's Hospital Montréal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Pia Wintermark

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Ejection fraction (EF) in % (reflecting left ventricular function) and tricuspid annular plane systolic excursion (TAPSE) in cm (reflecting right ventricular function) Secondary outcome to explore efficacy (cardiopulmonary hemodynamics) Day 2 to 4 of life
Primary Extent of brain injury Primary outcome to explore efficacy (brain injury) Day 30 of life, compared to day 2 of life
Secondary Serious adverse events Close monitoring for adverse events such as death, hypotension, persistent pulmonary hypertension, altered renal or hepatic function, etc to assess the safety of sildenafil Day 1 to 10 of life
See also
  Status Clinical Trial Phase
Completed NCT05471336 - Enteral Feeding and Splanchnic NIRS Values in Infants With Neonatal Encephalopathy (NE) N/A
Recruiting NCT05514340 - Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy Phase 2
Recruiting NCT04603547 - Transcutaneous Carbon Dioxide Monitoring in Neonates Receiving Therapeutic Hypothermia for Neonatal Encephalopathy
Completed NCT01913340 - Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO) Phase 1/Phase 2
Completed NCT00581581 - CoolCap Followup Study-Coordination of Participating Centers N/A
Recruiting NCT05772416 - Neonatal Neurological Examination to Detect Infants at Risk
Completed NCT03122808 - Uterine Activity in Moderate-Severe Neonatal Encephalopathy: A Case Control Study
Recruiting NCT02544100 - Neonatal Neurologic Intensive Care Network of China
Completed NCT03380013 - OMT to Improve Feeding After Hypothermia N/A
Active, not recruiting NCT03409770 - Optimising the Duration of Cooling in Mild Encephalopathy N/A
Recruiting NCT05127070 - Evaluating the NeoTree in Malawi and Zimbabwe
Not yet recruiting NCT05756296 - The Long-term Consequences of Neonatal Encephalopathy in the Hypothermia Era
Recruiting NCT04432662 - Darbepoetin in Neonatal Encephalopathy Trial Phase 2
Recruiting NCT02793999 - Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
Not yet recruiting NCT05889507 - Cooling in Mild Encephalopathy N/A
Recruiting NCT05848271 - Natural History Study of Patients With HPDL Mutations
Not yet recruiting NCT04176471 - TIME Study: Therapeutic Hypothermia for Infants With Mild Encephalopathy N/A
Completed NCT01309711 - Magnetic Resonance Biomarkers in Neonatal Encephalopathy
Recruiting NCT04225975 - Neonate Cerebral Activity in Immediate Post Partum N/A
Recruiting NCT05610085 - A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures Phase 2

External Links